|
|
|
| Effect evaluation of the low-dose hormone replacement therapy on menopausal-related symptoms of young patients with cervical squamous cell carcinoma |
| WU Wan-li*, LI Chun-ming, YING Qian, MA Lin-juan, ZHOU Jian-hong, YU Ai-jun
|
| Department of Gynecology,Zhejiang Cancer Hospital,Hangzhou,Zhejiang 310022,China |
|
|
|
|
Abstract Objective To evaluate the effect of low-dose hormone replacement therapy（HRT）on menopausal-related symptoms in young patients with cervical squamous cell carcinoma. Methods From March 2016 to September 2018,eighty patients aged 45 years below with cervical squamous cell carcinoma of stage Ⅰ-Ⅱ and iatrogenic menopause were recruited,who were diagnosed at Zhejiang Cancer Hospital and Women's Hospital Affiliated to Medical College of Zhejiang University. Fourty of them performed low dose HRT（1 mg estradiol valerate a day or 1.25 mg tibolone a day）,twenty performed standard dose HRT（1 mg estradiol valerate and 1.25 mg tibolone a day）,another twenty do not perform HRT as a control group. The levels of follicle stimulating hormone（FSH）,estradiol（E2）,menopausal symptoms（the improved Kupperman score）and incidence of side effects were assessed before and 1,3,6 months after the intervention. Results There were significant differences in E2 levels,FSH levels and improved Kupperman scores among the low dose group,the standard dose group and the control group（all P<0.05）. With the extension of intervention time,E2 levels in the low dose group and the standard dose group increased first and then decreased,FSH levels and improved Kupperman scores decreased（all P<0.05）. Compared with the control group,E2 levels,FSH levels and improved Kupperman scores in the standard dose group changed more significantly（all P<0.05）. E2 and FSH levels in the low dose group changed less than that in the standard dose group（all P<0.05）,while improved Kupperman scores was close to that in the standard dose group. The incidence rate of side effects in the low dose group was 2.50%,which was lower than 20.00% in the standard dose group（P<0.05）. Conclusion For young patients with cervical squamous cell carcinoma,using low dose HRT may less affects E2 and FSH levels than using the standard dose,but could achieve similar effects in treatment of menopausal-related symptoms.
|
|
Received: 16 April 2019
Revised: 28 July 2019
Published: 26 September 2019
|
|
|
|
|
|
[1] RASOO L N,ROSE P G.Fertility-perserving surgical procedures for patients with gynecologic maligancies[J]. Clin Obset Gynecol,2010,53(4):804-814.
[2] LACEY JV J R,BRINTON L A,BARNES W A,et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix[J]. Gynecol Oncol,2000, 77(1):149-154.
[3] PLOCH E.Hormonal replacement therapy in patients after cervical cancer treatment[J]. Gynecol Oncol,1987,26(2):169-177.
[4] YUK J S,LEE J H,JEON J D,et al.Menopause and blood mercury levels:the Korea national health and nutrition examination survey(KNHANES) 2008-2011[J]. Biol Trace Elem Res, 2014, 162(1-3):1-7.
[5] 李琳,吴洁,蒋小青,等. 江苏省妇女绝经相关因素的流行病学调查[J]. 中华妇产科杂志,2013,48(10):728-733.
[6] 王莉,王雅楠. 围绝经期和绝经后期妇女的生存质量及其与 Kupperman评分的相关性[J]. 中国老年学杂志,2011,31(8):2941-2943.
[7] 胡颖敏,蓝坚华,王佩英,等. 女性围绝经综合征危险因素分析[J]. 预防医学,2017,29(10):1051-1053.
[8] WALLACE W H,THOMSON A B,KELSEY T W.The radiosensitivity of the human oocyte[J]. Hum Reprod,2003 ,18:117-121.
[9] MOSS E L,TANEJA S,MUNIR F,et al.Iatrogenic Menopause after treatment for cervical cancer[J]. Clinical Oncology,2016,(28):766-775.
[10] IBEANU O,MODESITT S C,DUCIE J,et al.Hormone replacement therapy in gynecologic cancer survivors:why not?[J]. Gynecol Oncol,2011,122:447-454.
[11] GORDON J L,GIRDLER S S.Hormone replacement therapy in the treatment of perimenopausal depression[J]. Curr Psychiatry Rep,2014,16(12):517.
[12] 丁月华,金敏娟,王军. 围绝经期女性骨质疏松症激素替代治疗效果观察[J]. 预防医学,2018,30(5):533-535.
[13] 中华医学会妇产科学分会绝经学组. 绝经期管理与激素补充治疗临床应用指南(2012版)[J]. 中华妇产科杂志,2013,48(10):795-799.
[14] EBINA Y,MIKAMI M,NAGASE S,et al.Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer[J]. Int J Clin Oncol,2019,24(1):1-19.
[15] UTIAN W H,ARCHER D F,BACHMANN G A,et al.Estrogen and progestogen use in postmenopausal women:July 2008 position statement of The North American Menopausal Society[J].Menopause,2008,15(4):584-602.
[16] DE VILLIERS T J,HALL J E,PINKERTON J V,et al. Revised global consensus statement on menopausal hormone therapy[J].Climacteric,2016,19:313-315.
[17] 左宏玲,邓燕,王艳芳,等. 低剂量与标准剂量结合雌激素联合不同孕激素应用对围绝经期综合征患者骨密度的影响[J]. 中华妇产科杂志,2018 ,53(4):243-247.
[18] FILES J A,MILLER V M,CHA S S,et al.Effects of different hormone therapies on breast pain in recently postmenopausal women:findings from the Mayo Clinic KEEPS breast pain ancillary study[J]. Womens Health(Larchmt),2014,23(10):801-805.
[19] SCHIERBECK L.Primary prevention of cardiovascular disease with hormone replacement therapy[J]. Climacteric,2015,18(4):492-497.
[20] 纪红. 围绝经期综合征患者更年期症状评分及其影响因素[J]. 中华老年学杂志,2013,33(1):159-160.
[21] 李芸,宋阳,曲凡,等. 低剂量激素补充治疗对绝经后妇女生活质量的影响[J]. 中国医药导报,2015,12(8):70-73.
[22] 丁红岩,徐洪阁,高金瑜,等. 激素替代治疗对宫颈鳞状细胞癌患者术后性激素及肿瘤标志物的影响[J]. 海南医学院学报,2016,22(23):2858-2861. |
|
|
|
